PFSA
Profusa, Inc.
Healthcare — Medical Devices
Profusa, Inc., a digital health technology company, develops bioengineered sensors for body to detect and continuously transmit clinical-grade data for personal and medical use in the United States. It offers the Lumee Oxygen Platform to monitor compromised tissue for peripheral artery disease, chronic wounds, and reconstructive surgery. The company researches and develops the Lumee Glucose Platform which is designed to monitor glucose levels in interstitial fluid. Profusa, Inc. is based in Berkeley, California.
None
$1.87
$-0.11 (-5.56%)
Price History
52-Week Range
Sign in to add PFSA to a watchlist or set price alerts.
Fundamentals
| Market Cap | 605.8K |
| P/E Ratio (TTM) | - |
| Forward P/E | - |
| EPS (TTM) | $-15.36 |
| Dividend Yield | - |
| Profit Margin | - |
| Revenue Growth | - |
| ROE | - |
| Debt/Equity | - |
| Recommendation | None |
| Analyst Target | - |
| Analysts | - |
| Next Earnings | - |
| Indexes | - |
Technical Indicators
| RSI (14) | 29.4 |
| Beta | 0.32 |
| SMA 20 | - |
| SMA 40 | - |
| 52-Week High | $412.50 |
| 52-Week Low | $0.10 |
| 50-Day Avg | $0.36 |
| 200-Day Avg | $7.72 |
| Avg Volume | $1.15M |
| Volume | 44.5K |
Performance Analysis
BULLISHPFSA shows predominantly bullish signals based on its fundamentals and technicals.
+
Trading near its 52-week low ($0.10), which could present a value opportunity.
+
RSI at 29.4 signals oversold conditions — a bounce may be ahead.
~
Wall Street consensus is "none".
Recent News
Loading news...
Last updated: Jul 02, 2026 13:26 UTC
Back to Screener Export Report